DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death, with a limited response to immune checkpoint inhibitors (ICIs). Discoidin domain receptor 1 (DDR1) is a collagen-binding kinase that is implicated in tumor progression and immune escape, but its role in NSCLC is unclear. This study aimed to clarify the clinical significance and therapeutic potential of DDR1 via bioinformatics, machine learning, in vitro experiments, and clinical sample analysis.

Materials and methods

NSCLC patients were stratified by DDR1 expression based on retrospective RNA-seq data from The Cancer Genome Atlas (TCGA); after quality control, 495 lung adenocarcinoma (LUAD) and 481 lung squamous cell carcinoma (LUSC) tumor samples, together with 57 LUAD an

SUBMITTER: Lu R 

PROVIDER: S-EPMC12698539 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature